Result of Annual General Meeting (1639935)

Arix Bioscience PLC (ARIX) Result of Annual General Meeting 23-May-2023 / 16:30 GMT/BST

-----------------------------------------------------------------------------------------------------------------------

Arix Bioscience plc

Result of Annual General Meeting

LONDON, 23 May 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's .

                                                                            VOTES            TOTAL      % of   VOTES 
No            RESOLUTION                                 VOTES FOR  %       AGAINST   %      VOTES      ISC    WITHHELD 
                                                                                                        VOTED 
 
              To receive the Directors' Report and the 
1             accounts of the Company for the year ended 68,931,411 100.00% 3,441     0.00%  68,934,852 53.28% 8,440 
              31 December 2022 
 
 
              To approve the Directors' Remuneration 
2             Report                                     61,073,950 89.25%  7,358,207 10.75% 68,432,157 52.89% 511,135 
 
 
              To re-elect Peregrine Moncreiffe as a 
3             Director                                   68,099,019 98.79%  834,821   1.21%  68,933,840 53.28% 9,452 
 
 
              To re-elect Maureen O'Connell as a 
4             Director                                   68,894,053 99.94%  42,077    0.06%  68,936,130 53.28% 7,162 
 
 
5             To re-elect Isaac Kohlberg as a Director   68,900,656 99.98%  17,184    0.02%  68,917,840 53.26% 25,452 
 
 
6             To re-elect Robert Lyne as a Director      68,902,689 99.95%  31,595    0.05%  68,934,284 53.28% 9,008 
 
 
7             To elect Dr. Debra Barker as a Director    68,907,528 99.95%  32,248    0.05%  68,939,776 53.28% 3,516 
 
 
8             To elect Andrew Smith as a Director        68,921,195 99.98%  13,089    0.02%  68,934,284 53.28% 9,008 
 
 
              To appoint BDO LLP as auditors of the 
9             Company                                    68,929,881 99.99%  7,445     0.01%  68,937,326 53.28% 5,966 
 
 
              To authorise the Audit and Risk Committee 
10            of the Company to fix the auditor's        68,934,245 100.00% 2,013     0.00%  68,936,258 53.28% 7,034 
              remuneration 
 
 
11            To authorise the Directors to allot shares 65,989,256 95.72%  2,950,520 4.28%  68,939,776 53.28% 3,516 
 
 
              Authority to disapply statutory pre- 
12            emption rights                             62,199,252 90.23%  6,734.680 9.77%  68,933,932 53.28% 9,360 
 
 
              Additional authority to disapply statutory 
13            pre- emption rights                        62,202,105 90.23%  6,731,827 9.77%  68,933,932 53.28% 9,360 
 
 
              To authorise the Company to purchase its 
14            own shares                                 68,921,128 99.98%  17,177    0.02%  68,938,305 53.28% 4,987 
 
 
              Authority to call a general meeting, other 
15            than an annual general meeting, on not     68,145,351 98.85%  792,954   1.15%  68,938,305 53.28% 4,987 
              less than 14 clear days' notice 
 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at .

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations .

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

[phone]

[e-mail]

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

ISIN:           GB00BD045071 
Category Code:  RAG 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   245804 
EQS News ID:    1639935 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1639935&application_name=news

(END) Dow Jones Newswires

May 23, 2023 11:30 ET (15:30 GMT)